• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.56% Nasdaq Down0.79%

    Celgene Corporation (CELG)

    -NasdaqGS
    100.90 Down 2.32(2.25%) 4:00PM EDT
    |After Hours : 100.90 0.00 (0.00%) 4:22PM EDT
    ProfileGet Profile for:
    Celgene Corporation
    86 Morris Avenue
    Summit, NJ 07901
    United States - Map
    Phone: 908-673-9000
    Website: http://www.celgene.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:6,971

    Business Summary 

    Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet's disease, atopic dermatitis, and ulcerative colitis. The company’s products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treatment of patients with diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; and Juno Therapeutics, Inc., as well as a strategic collaboration with Nurix, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Celgene Corporation

    Corporate Governance 
    Celgene Corporation’s ISS Governance QuickScore as of May 1, 2016 is 2. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 1; Compensation: 4.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert J. Hugin MBA, 61
    Exec. Chairman and Chairman of Exec. Committee
    9.10M0.00
    Mr. Mark J. Alles , 57
    Pres, Chief Operating Officer and Director
    4.33M10.42M
    Mr. Peter N. Kellogg BSE, MBA, 60
    Chief Financial Officer and Exec. VP
    2.23M0.00
    Dr. Jacqualyn A. Fouse Ph.D., 55
    Pres of Global Hematology & Oncology and Director
    4.54M0.00
    Dr. Thomas O. Daniel M.D., 62
    Chairman of Celgene Research
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders